Cancer Treatment Registry




Login


Herceptin

Category: Adjunctive to Chemo & Radiation

Other Names: Trastuzumab

Herceptin is a humanized monoclonal antibody that acts on the HER2/neu (erbB2) receptor. Trastuzumab's principal use is as an anti-cancer therapy in breast cancer in patients whose tumors over-express (that is, "produce more than the usual amount of") this receptor. Trastuzumab is administered either once a week or once every three weeks intravenously for 30 to 90 minutes.

In one British trial this translated as follows: 9.4% of those on the drug relapsed as opposed to the 17.2% of those not on trastuzumab. In this study, almost five out of six patients would not have developed a recurrence during the study whether or not they received trastuzumab, and almost one in ten patients relapsed despite it and therefore received no apparent benefit from the treatment. Only one patient in 13 received positive benefit in terms of cancer recurrence. However, these numbers solely consider the risk of a cancer recurrence and do not account for morbidity and mortality (sickness and death) due to the treatment's side effects.

Google it: Herceptin

Add A Comment


NEWS

Newest Member   User name: JohnD
  Location: Add Other Location     
  Washington, 98382 Age: 69

Newest Treatment MSQ Nutritional Therapy
Type: Nutritional

Most Viewed IP6
Type: Nutritional

Most Used Treatment Chemotherapy
Type: Chemotherapy




Home View-Patients View-Treatments View-Statistics View-Doctors Sitemap Sponsors Contact